v3.25.3
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating expenses:        
Research and development, net of grants $ 4,519 $ 4,203 $ 13,496 $ 11,442
General and administrative, net of grants 2,206 2,106 7,250 6,775
Total operating expenses 6,725 6,309 20,746 18,217
Loss from operations (6,725) (6,309) (20,746) (18,217)
Other income, net 195 268 770 781
Net loss $ (6,530) $ (6,041) $ (19,976) $ (17,436)
Net loss per common share - basic (in dollars per share) $ (0.11) $ (0.11) $ (0.34) $ (0.32)
Net loss per common share - diluted (in dollars per share) $ (0.11) $ (0.11) $ (0.34) $ (0.32)
Weighted average common shares outstanding - basic (in shares) 59,711 55,247 59,399 54,161
Weighted average common shares outstanding - diluted (in shares) 59,711 55,247 59,399 54,161

Source